Sutezolid

Drug Profile

Sutezolid

Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Developer Sequella
  • Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-II for Tuberculosis (Treatment-naive) in South Africa (PO)
  • 27 Jul 2015 No recent reports on development identified - Phase-I for Tuberculosis (In volunteers) in USA (PO)
  • 09 Aug 2013 Pfizer terminates its involvement in the development of sutezolid
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top